Finally, the arrival of personalized (or precision) medicine may shed some light on the angiogenic mechanisms employed by the tumor mass, such as information on the presence of VM, VCO and tumor metabolism (among many other possible variables) needed to complement the levels of proangiogenic factors such as angiopoietin or VEGF. The gene discussed is VEGFA; the disease is neoplasm.